Skip to content

Infectiology

Active Private limited companyfounded 2022active for 4 yearsBrugmannlaan 266, 1180 UccleKBO/BCE: BE 0793.688.939

Lifetime

4 annual accounts with figures on one time axis
peak of €90,807 in 2023
€53,853▼ 19.7%
peak of €64,091 in 2023
€29,050▼ 39.5%
peak of €122,776 in 2024
€24,473▼ 80.1%
€63,485▲ 93.7%
Board1 name since 2022
1 director
Documentsfilings and deeds
07-07-202624 days before the deadline
2025micro format
Gross margin from €67,094 to €53,853Result from €48,039 to €29,050Registered office moved from Genappe to Uccle 06-11Dividend €127,353Equity from €122,776 to €24,473Debts from €32,771 to €63,485

Key points

from the 2025 annual accounts

Equity

€24,473 from €122,776 in 2024

Equity fell by 80% in 1 year.

Turnover

≈ €120,000 estimated

The micro format states no turnover.

Debts

€63,485 72% of the balance sheet
Suppliers 9%Taxes and wages 20%Other 71%

Liquidity

1.03 was 3.71 in 2024

Short-term debts rose from €32,771 to €63,485.

Filings

4 annual accounts 3 late
AprilJune31 JulyOctober2022202320242025

The 2022 accounts came in latest, 164 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 7,983 companies had the same profile as Infectiology has now. Each dot stands for 20 companies, two years later.

94.3%
were still trading
1.9%
stopped another way
3.7%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 7,983 companies, not a prediction for Infectiology. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 17-11-2022
  • 100 sharesdeed of 21-11-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0793688939
Registered office moved from Genappe to Uccle The registered office moved from Grand route 50, 1474 Genappe to avenue Brugmann 266, 1180 Uccle · General meeting of 15-10-2025 · Gazette deed
Incorporation Founding capital of €3,000, 100 shares · Founded by · appointed as director · published on 21-11-2022 · Gazette deed
First establishment Grand route 50, Genappe
All 11 events

Comparable companies

same main activity, similar in size and age
Company
Infectiology Uccle €87,957 €53,853 27.8% -
MEDICAL HAIR TRANSPLANT Auderghem €94,117 €54,674 46.0% -
Docteur A. Hansenne Halle €79,461 €53,692 79.2% -
VIKAS België Bruges €83,143 €49,212 -13.6% 1
Osteo Eyben Maaseik €95,746 €58,811 62.0% -
VALENTINE WEBER SRL Waterloo €102,021 €55,845 92.8% -
Cabinet CCA DW Uccle €80,238 €63,986 2.5% -

These companies have the same main activity as Infectiology: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €79,500 and €102,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 17-11-2022Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.339.256.4531474 Genappe, since 17-11-2022
Financial year end
31 December
Peppol
Reachable since 29-12-2025
Company details

Annual accounts 2025

€87,957▼ 43.5%
Filing
Filed on 07-07-2026, 24 days before the end of the filing period
Financials

Insights on Infectiology

Infectiology files the micro format. That format states no turnover. The gross margin rose from €11,644 in 2022 to €53,853 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Infectiology

What is the company number of Infectiology?
The company number of Infectiology is 0793.688.939. The VAT number is the same number with BE in front: BE 0793.688.939.
Where is Infectiology based?
The registered office is at Brugmannlaan 266, 1180 Uccle.Company details
What does Infectiology do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Infectiology?
Infectiology is a private limited company (BV).
When was Infectiology founded?
Infectiology was founded on 17-11-2022.
Is Infectiology still active?
Yes, Infectiology is an active enterprise in the KBO register.
What is the turnover of Infectiology?
The turnover in financial year 2025 is about €120,000. This figure is estimated from the gross margin of €53,853 and 33 comparable companies (NACE 862). It probably lies between €91,000 and €150,000.Financials
Is Infectiology profitable?
In financial year 2025, Infectiology made a profit of €29,050.
Where can I find the annual accounts of Infectiology?
Infectiology filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Infectiology due?
Infectiology must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.